Suppr超能文献

Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study.

作者信息

Han Chengtao, Mengual Lourdes, Kang Bin, Lozano Juan José, Yang Xiaoqun, Zhang Cuizhu, Alcaraz Antonio, Liang Ji, Ye Dingwei

机构信息

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

出版信息

J Cancer. 2018 Aug 6;9(17):3208-3215. doi: 10.7150/jca.24506. eCollection 2018.

Abstract

Current standard methods used to detect and monitor bladder cancer (BC) are invasive or have low sensitivity. We have previously reported in an international European study four non-invasive tests for BC diagnosis based on the gene expression patterns of urine. to validate the tests in an independent Asian cohort. Prospective blinded study in which consecutive voided urine samples from BC patients and controls (n=520) were collected in the Fudan University Shanghai Cancer Center from 2014-2016. Gene expression values were quantified using TaqMan Arrays. The same cut-off as previously reported for discrimination between tumours and controls was used in this validation study. Finally, a total of 257 tumour and 132 control urine samples were analysed. We found a high accuracy for the four gene classifiers in this independent Asian set, the classifiers composed of 5 and 10 genes achieved the best sensitivity (80.54% and 81.32%, respectively) maintaining a high specificity (91.67% and 85.61%, respectively). Sensitivity of 5-gene (GS_D5) and 10-gene (GS_D10) expression classifiers in recurrent BC cases (78 and 79%, respectively) is comparable to that of primary BC cases (82%). Cytology and NMP22 identified 67% and 40%, respectively, of tumours that have been diagnosed with our tests. In addition, influence of each studied gene was analyzed and showed similar gene rank between Chinese and Caucasian population. Our study proves that our non-invasive diagnostic BC tests can be reproduced in independent cohorts and in an external laboratory. All the four gene classifiers have shown equal or superior performance to the current gold standard in the present and previously reported validation studies. Consequently, they may be taken for consideration as molecular tests applicable to clinical practice in the management of BC. Our gene classifiers achieve sensitivities up to 90% in HR NMIBC and MIBC patients, while this achievement is comparatively lower in LR NMIBC ones.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3b/6134826/790a74b3dc13/jcav09p3208g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验